Medtronic (MDT) Offering Possible 9.17% Return Over the Next 3 Calendar Days

Medtronic's most recent trend suggests a bearish bias. One trading opportunity on Medtronic is a Bear Call Spread using a strike $127.00 short call and a strike $132.00 long call offers a potential 9.17% return on risk over the next 3 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $127.00 by expiration. The full premium credit of $0.42 would be kept by the premium seller. The risk of $4.58 would be incurred if the stock rose above the $132.00 long call strike price.

The 5-day moving average is moving down which suggests that the short-term momentum for Medtronic is bearish and the probability of a decline in share price is higher if the stock starts trending.

The 20-day moving average is moving down which suggests that the medium-term momentum for Medtronic is bearish.

The RSI indicator is at 32.52 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here

LATEST NEWS for Medtronic

New Survey Identifies Opportunity to Improve Shared Decision Making Between Cardiologists and Heart Valve Disease Patients
Fri, 14 May 2021 13:00:00 +0000
New findings from an American College of Cardiology's (ACC) survey revealed more than half of cardiologists (57%) believe patient preparation may lead to better quality discussions around treatment options for heart valve disease (HVD). Results from the ACC CardioSurve panelist survey, sponsored by Medtronic (NYSE: MDT), and conducted by the American College of Cardiology, garnered responses from more than 150 cardiologists around key factors driving treatment choices for patients with symptomatic severe aortic stenosis. The data was published in the April 2021 Cardiology Magazine and will be presented Sunday during the virtual symposium at ACC's 70th Annual Scientific Session, A Practical Approach to Shared Decision-Making when Treating HVD.

The Zacks Analyst Blog Highlights: Mastercard, Home Depot, Disney, Netflix and Medtronic
Fri, 14 May 2021 11:15:11 +0000
The Zacks Analyst Blog Highlights: Mastercard, Home Depot, Disney, Netflix and Medtronic

Medtronic to Announce Financial Results for its Fourth Quarter and Full Fiscal Year 2021
Thu, 13 May 2021 15:00:00 +0000
Medtronic plc (NYSE:MDT) announced today that it will report financial results for its fourth quarter and full fiscal year 2021 on Thursday, May 27, 2021. A news release will be issued at approximately 5:45 a.m. Central Daylight Time (CDT) and will be available at https://newsroom.medtronic.com. The news release will include summary financial information for the company's fourth quarter and fiscal year 2021, which ended on Friday, April 30, 2021.

Medtronic and Medtronic Foundation Partner to Address COVID-19 Surges with Focus on Equity
Thu, 13 May 2021 13:00:00 +0000
Medtronic plc (NYSE:MDT) and the Medtronic Foundation announced an additional $3M USD for COVID-19 relief efforts – a combination of financial resources, personal protective equipment (PPE) donations, and Medtronic employee engagement – focused on underserved areas of India, Brazil, the United States, and other global regions. This latest COVID-19 response expands Medtronic and Medtronic Foundation's COVID-19 support to $56M USD.

MedTech Round Up: Update On Lucira Health, Second Sight Medical ClearPoint Neuro, Medtronic, Sientra
Wed, 12 May 2021 16:47:34 +0000
Lucira Health Inc (NASDAQ: LHDX) has announced that its Lucira Check IT COVID-19 test kit is now available on Amazon.com in the US. Each Lucira Check IT test kit provides a PCR quality test result at home in 30 minutes or less. The product costs $55. Price Action: LHDX shares are trading 14.3% higher at $5.82 during the market session on the last check Wednesday. Second Sight Medical Products Inc (NASDAQ: EYES) has announced two-year results of its Early Feasibility Study of the Orion Visual Cortical Prosthesis. Data showed that all five patients tested at the two-year mark could locate a white square on a dark computer screen significantly better with the Orion System on than with it off. 4/5 were able to identify better the direction of motion of a bar moving across a computer screen. Orion is an implanted cortical stimulation device intended to provide useful artificial vision to individuals who are blind due to a wide range of causes. Price Action: EYES shares are trading 43.6% higher at $7.18 during the market session on the last check Wednesday. View more earnings on CLPT ClearPoint Neuro Inc (NASDAQ: CLPT) announced FDA clearance for its SmartFrame Array, a navigation system designed for use in both the MRI suite and operating room. The company reported Q1 sales of $4.03 million, which beat the analyst consensus estimate of $3.27 million, and up 29% Y/Y. It sees sales in the range of $16-$17.5 million for the 2021 calendar year, better than the consensus of $15.83 million. Price Action: CLPT shares are trading 1.67% higher at $17.96 during the premarket session on the last check Wednesday. Medtronic Plc (NYSE: MDT) is recalling HeartWare HVAD System to provide updated Instructions due to safety issues with Carrying Cases, Driveline Cover Orientation, and Controller Power-Up Sequence. HVAD System helps the heart continue to pump blood to the rest of the body. The faulty devices may cause serious patient harm, including death. There have been one death and 64 injuries reported to the FDA for these issues. Price Action: MDT shares are trading 1.56% lower at $123.27 during the market session on the last check Wednesday. Sientra Inc (NASDAQ: SIEN) has agreed to sell its miraDry business to 1315 Capital, a healthcare growth equity firm. Deal terms were not disclosed. The miraDry system provides a non-invasive treatment that offers a lasting solution for underarm sweat. It reported Q1 2021 sales of $23.2 million, a 37% Y/Y increase and beating the consensus estimate of $18.8 million. Sientra sees full-year 2021 breast products sales in the range of $72 to $76 million, representing 31%-38% growth Y/Y, compared to previous guidance of $70 million to $74 million. Price Action: SIEN shares are trading 5.3% lower at $6.38 during the market session on the last check Wednesday. See more from BenzingaClick here for options trades from BenzingaMedTech Round Up: Update On Products By Conformis, Medtronic, Orthofix, Neovasc© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.